Literature DB >> 11223969

Predictive factors for long-term engraftment of autologous blood stem cells.

P R Duggan1, D Guo, J Luider, I Auer, J Klassen, A Chaudhry, D Morris, S Glück, C B Brown, J A Russell, D A Stewart.   

Abstract

Data from 170 consecutive patients aged 19-66 years (median age 46 years) who underwent unmanipulated autologous blood stem cell transplant (ASCT) were analyzed to determine if total CD34+ cells/kg infused, CD34+ subsets (CD34+41+, CD34+90+, CD34+33-, CD34+38-, CD34+38-DR-), peripheral blood CD34+ cell (PBCD34+) count on first apheresis day, or various clinical factors were associated with low blood counts 6 months post ASCT. Thirty-four patients were excluded from analysis either because of death (n = 17) or re-induction chemotherapy prior to 6 months post ASCT (n = 13), or because of lack of follow-up data (n = 4). Of the remaining 136 patients, 46% had low WBC ( < 4 x 10(9)/l), 41% low platelets (<150 x 10(9)/l), and 34% low hemoglobin ( < 120 g/l) at a median of 6 months following ASCT. By Spearman's rank correlation, both the total CD34+ cell dose/kg and the PBCD34+ count correlated with 6 month blood counts better than any subset of CD34+ cells or any clinical factor. The PBCD34+ count was overall a stronger predictor of 6 month blood counts than was the total CD34+ cells/kg infused. Both factors retained their significance in multivariate analysis, controlling for clinical factors. In conclusion, subsets of CD34+ cells and clinical factors are inferior to the total CD34+ cell dose/kg and PBCD34+ count in predicting 6 month blood counts following ASCT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11223969     DOI: 10.1038/sj.bmt.1702708

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  Autologous stem cell transplantation in hematological malignancies.

Authors:  Norbert-Claude Gorin
Journal:  Springer Semin Immunopathol       Date:  2004-10-07

2.  Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.

Authors:  P Quittet; P Ceballos; E Lopez; Z Y Lu; P Latry; C Becht; E Legouffe; N Fegueux; C Exbrayat; D Pouessel; V Rouillé; J P Daures; B Klein; J F Rossi
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

3.  Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial.

Authors:  Kosar Raoufinejad; Ahmad Reza Shamshiri; Shahrzad Pezeshki; Bahram Chahardouli; Molouk Hadjibabaie; Zahra Jahangard-Rafsanjani; Kheirollah Gholami; Mehdi Rajabi; Mohammad Vaezi
Journal:  Daru       Date:  2019-11-11       Impact factor: 3.117

Review 4.  A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes.

Authors:  Mohammad Rafiee; Mohammad Abbasi; Hassan Rafieemehr; Amin Mirzaeian; Mohieddin Barzegar; Vahid Amiri; Shaghayegh Shahsavan; Mohammad Hossein Mohammadi
Journal:  Health Sci Rep       Date:  2021-05-07

5.  Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers.

Authors:  Alissa Visram; Christopher Bredeson; David Allan; Mitchell Sabloff; Lothar Huebsch; Jason Tay; Natasha Kekre; Sheryl McDiarmid; Ranjeeta Mallick; Alan Tinmouth; Lisa Martin; Linda Hamelin; Dawn Maze
Journal:  Blood Cancer J       Date:  2018-01-29       Impact factor: 11.037

6.  Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative Disease Patients: Factors Influencing Engraftment.

Authors:  Mohd Nazri Hassan; Hafizuddin Mohamed Fauzi; Azlan Husin; Rapiaah Mustaffa; Rosline Hassan; Mohd Ismail Ibrahim; Noor Haslina Mohd Noor
Journal:  Oman Med J       Date:  2019-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.